SPOTLIGHT: Novartis highlights cancer pipeline


Accentuate the positive: That's Novartis' motto. The company's head of oncology announced today that the company has 25 cancer drugs in either phase I or phase II, predicting at least one new drug or new indication within seven years. Report

Suggested Articles

A few years ago, one of our Fierce editors met a Big Pharma R&D chief for the first time. “You’re the ones with the scary name,” he joked.

Pfizer's eczema hopeful has been building its case to challenge Sanofi and Regeneron's Dupixent, but safety issues could stand in its way.

Cedrik Britten, M.D., becomes the biotech’s new chief medical officer to help run its adoptive cell therapy and TCR bispecifics platform.